ALBANY, N.Y.--(BUSINESS WIRE)--Albany Molecular Research, Inc. (NASDAQ: AMRI) today announced the selection of a compound from its proprietary oncology research program for advanced preclinical testing, with the goal of submitting an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration in 2007.
